Works matching IS 01676997 AND DT 2024 AND VI 42 AND IP 6

Results: 13

Manganese improves anti-PD-L1 immunotherapy via eliciting type I interferon signaling in melanoma.

Published in:

Investigational New Drugs, 2024, v. 42, n. 6, p. 685, doi. 10.1007/s10637-024-01484-6

By:

Zhang, Xiaoxin;
Deng, Jianhua;
Wu, Renjie;
Hu, Jian

Publication type:

Article

Efficacy of immune checkpoint inhibitor rechallenge in initial immunotherapy responders with advanced non-small cell lung cancer: A single-center retrospective study.

Published in:

Investigational New Drugs, 2024, v. 42, n. 6, p. 703, doi. 10.1007/s10637-024-01483-7

By:

xu, Manyi;
Wang, Yanhua;
Wang, Ke;
Hao, Yue;
Xu, Chunwei;
Shi, Lei;
Song, Zhengbo

Publication type:

Article

Phase II trial of multi-tyrosine kinase inhibitor ESK981 in combination with PD-1 inhibitor nivolumab in patients with metastatic castration-resistant prostate cancer.

Published in:

Investigational New Drugs, 2024, v. 42, n. 6, p. 675, doi. 10.1007/s10637-024-01482-8

By:

Heath, Elisabeth I.;
Chen, Wei;
Choi, Jae E.;
Dobson, Kimberlee;
Smith, Melanie;
Maj, Tomasz;
Kryczek, Ilona;
Zou, Weiping;
Chinnaiyan, Arul M.;
Qiao, Yuanyuan

Publication type:

Article

Modernizing the assessment and reporting of adverse events in oncology clinical trials using complementary statistical approaches: a case study of the MOTIVATE trial.

Published in:

Investigational New Drugs, 2024, v. 42, n. 6, p. 664, doi. 10.1007/s10637-024-01481-9

By:

Morisseau, Mathilde;
Gomez-Roca, Carlos;
Viala, Marie;
Rabeau, Audrey;
Loirat, Delphine;
Munsch, Nadia;
Thomas, Kristell;
Pages, Cécile;
Korakis, Iphigenie;
Sibaud, Vincent;
Delord, Jean-Pierre;
Filleron, Thomas;
Cabarrou, Bastien

Publication type:

Article

A phase II study of ME2136 (Asenapine Maleate) plus standard antiemetic therapy for patients, including diabetic patients, receiving cisplatin-based chemotherapy.

Published in:

Investigational New Drugs, 2024, v. 42, n. 6, p. 655, doi. 10.1007/s10637-024-01480-w

By:

Hamauchi, Satoshi;
Yasui, Hirofumi;
Yokota, Tomoya;
Tsushima, Takahiro;
Fushiki, Kunihiro;
Naito, Tateaki;
Ono, Akira;
Kado, Nobuhiro;
Onozawa, Yusuke;
Murakami, Haruyasu;
Takahashi, Toshiaki;
Hirashima, Yasuyuki;
Mori, Keita;
Yamazaki, Kentaro

Publication type:

Article

Anti-ovarian cancer migration and toxicity characteristics of a platinum(IV) pro-drug with axial HDAC inhibitor ligands in zebrafish models.

Published in:

Investigational New Drugs, 2024, v. 42, n. 6, p. 644, doi. 10.1007/s10637-024-01479-3

By:

Begum, Salma;
Irvin, Scheldon D.;
Cox, Carol K.;
Huang, Zhouyang;
Wilson, Justin J.;
Monroe, Jerry D.;
Gibert, Yann

Publication type:

Article

Unraveling the potential biomarkers of immune checkpoint inhibitors in advanced ovarian cancer: a comprehensive review.

Published in:

Investigational New Drugs, 2024, v. 42, n. 6, p. 728, doi. 10.1007/s10637-024-01478-4

By:

Na, Jian-rong;
Liu, Yaqin;
Fang, Kun;
Tan, Yuan;
Liang, Pan-pan;
Yan, Mei;
Chu, Jiao-jiao;
Gao, Jian-mei;
Chen, Dongsheng;
Zhang, Shu-xiang

Publication type:

Article

Predictive value of ZFHX4 mutation for the efficacy of immune checkpoint inhibitors in non-small cell lung cancer and melanoma.

Published in:

Investigational New Drugs, 2024, v. 42, n. 6, p. 623, doi. 10.1007/s10637-024-01477-5

By:

Fu, Cong;
Gu, Haoran;
Sun, Lin;
Wang, Zhouyu;
Zhang, Qin;
Luo, Ningning;
Chen, Dongsheng;
Zhou, Tong

Publication type:

Article

Clinical research progress of fruquintinib in the treatment of malignant tumors.

Published in:

Investigational New Drugs, 2024, v. 42, n. 6, p. 612, doi. 10.1007/s10637-024-01476-6

By:

Zhao, Shihao;
Wang, Wenhui;
Li, Jingyi;
Li, Zhigang;
Liu, Zhanbo;
Zhang, Shunchao;
Chen, Zhaoqi;
Wang, Hongling;
Wang, Xiangqi;
Wang, Juntao

Publication type:

Article

Gremlin1: a BMP antagonist with therapeutic potential in Oncology.

Published in:

Investigational New Drugs, 2024, v. 42, n. 6, p. 716, doi. 10.1007/s10637-024-01474-8

By:

Jin, Zhao;
Cao, Yanshuo

Publication type:

Article

Targeting MDM2-mediated suppression of p53 with idasanutlin: a promising therapeutic approach for acute lymphoblastic leukemia.

Published in:

Investigational New Drugs, 2024, v. 42, n. 6, p. 603, doi. 10.1007/s10637-024-01473-9

By:

Gungordu, Seyda;
Aptullahoglu, Erhan

Publication type:

Article

Exposure-response relationships of venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory t(11;14) multiple myeloma patients.

Published in:

Investigational New Drugs, 2024, v. 42, n. 6, p. 635, doi. 10.1007/s10637-024-01471-x

By:

Badawi, Mohamed Ali;
Engelhardt, Benjamin;
Dobkowska, Edyta;
Deng, Rong;
Kaufman, Jonathan L.;
Menon, Rajeev;
Salem, Ahmed Hamed

Publication type:

Article

Neoadjuvant immunochemotherapy in locally advanced laryngeal cancer and hypopharyngeal cancer: higher objective response rate and organ-preservation rate.

Published in:

Investigational New Drugs, 2024, v. 42, n. 6, p. 694, doi. 10.1007/s10637-024-01456-w

By:

Chen, Shaoshi;
Zhong, Qi;
Zhang, Shurong;
Zhang, Yang;
Hou, Lizhen;
Ma, Hongzhi;
He, Shizhi;
Lian, Meng;
He, Yurong;
Wang, Ru;
Fang, Jugao

Publication type:

Article